MUMBAI, India, Sept. 26 -- Intellectual Property India has published a patent application (202517084610 A) filed by Merck Sharp & Dohme Llc, Rahway, U.S.A., on Sept. 5, for 'formulations comprising actriia polypeptide variants.'
Inventor(s) include Sadineni, Vikram; Bhiwankar, Meena Nikhil; and Liu, Xiaoqing.
The application for the patent was published on Sept. 26, under issue no. 39/2025.
According to the abstract released by the Intellectual Property India: "In certain aspects, the present disclosure provides lyophilized pharmaceutical formulations comprising a recombinant fusion protein comprising an extracellular domain (ECD) of human activin receptor type-IIA (ActRIIa) proteins or derivatives thereof linked to a constant domain of an immunoglobulin, such as human IgG1 Fc domain and one or more pharmaceutical additives and/or excipients."
The patent application was internationally filed on Jan. 29, 2024, under International application No.PCT/US2024/013378.
Disclaimer: Curated by HT Syndication.
